A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment

Sydney C. Yuen, Adaeze Q. Amaefule, Hannah H. Kim, Breanna-Verissa Owoo, Emily F. Gorman and T. Joseph Mattingly ()
Additional contact information
Sydney C. Yuen: University of Maryland School of Pharmacy
Adaeze Q. Amaefule: University of Maryland School of Pharmacy
Hannah H. Kim: University of Maryland School of Pharmacy
Breanna-Verissa Owoo: University of Maryland School of Pharmacy
Emily F. Gorman: Health Sciences and Human Services Library, University of Maryland
T. Joseph Mattingly: University of Maryland School of Pharmacy

PharmacoEconomics - Open, 2022, vol. 6, issue 1, No 3, 9-19

Abstract: Abstract Background Hepatocellular carcinoma (HCC) is associated with significant financial burden for patients and payers. The objective of this study was to review economic models to identify, evaluate, and compare cost-effectiveness estimates for HCC treatments. Methods A systematic search of the PubMed, Embase, and Cochrane Library databases to identify economic evaluations was performed and studies that modeled treatments for HCC reporting costs and cost effectiveness were included. Risk of bias was assessed qualitatively, considering costing approach, reported study perspective, and funding received. Intervention costs were adjusted to 2021 US dollars for comparison. For studies reporting quality-adjusted life-years (QALYs), we conducted analyses stratified by comparison type to assess cost effectiveness at the time of the analysis. Results A total of 27 studies were included. Non-curative versus non-curative therapy comparisons were used in 20 (74.1%) studies, curative versus curative comparisons were used in 5 (18.5%) studies, and curative versus non-curative comparisons were used in 2 (7.4%) studies. Therapy effectiveness was estimated using a QALY measure in 20 (74.1%) studies, while 7 (25.9%) studies only assessed life-years gained (LYG). A health sector perspective was used in 26 (96.3%) of the evaluations, with only 1 study including costs beyond this perspective. Median intervention cost was $53,954 (range $4550–$4,760,835), with a median incremental cost of $6546 (range − $72,441 to $1,279,764). In cost-utility analyses, 11 (55%) studies found the intervention cost effective using a $100,000/QALY threshold at the time of the study, with an incremental cost-effectiveness ratio (ICER) ranging from − $1,176,091 to $1,152,440 when inflated to 2021 US dollars. Conclusion The majority of HCC treatments were found to be cost effective, but with significant variation and with few studies considering indirect costs. Standards for value assessment for HCC treatments may help improve consistency and comparability.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-021-00298-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:1:d:10.1007_s41669-021-00298-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-021-00298-z

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().